scholarly journals The impact of the COVID‐19 pandemic on skin cancer incidence and treatment in England, 2020

2021 ◽  
Author(s):  
Z.C. Venables ◽  
S. Ahmed ◽  
T. Bleiker ◽  
J. Broggio ◽  
M. Kwiatkowska ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Cancer Incidence ◽  
The Impact

The impact of ozone depletion on skin cancer incidence: An assessment of the Netherlands and Australia

1996 ◽  
Vol 1 (4) ◽  
pp. 229-240 ◽  
Author(s):  
W. J. M. Martens ◽  
M. G. J. den Elzen ◽  
H. Slaper ◽  
P. J. M. Koken ◽  
B. A. T. Willems
Keyword(s):  
Skin Cancer ◽  
The Netherlands ◽  
Cancer Incidence ◽  
Ozone Depletion ◽  
The Impact

The impact of ozone depletion on skin cancer incidence in Korea

2013 ◽  
Vol 169 (5) ◽  
pp. 1164-1165 ◽  
Author(s):  
S.G. Lee ◽  
N.Y. Ko ◽  
S.W. Son ◽  
H.J. Bae ◽  
J.S. Ha ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Cancer Incidence ◽  
Ozone Depletion ◽  
The Impact

scholarly journals Screening for Melanoma and Other Skin Cancer Shows a Higher Early Melanoma Incidence: Social Educational Program “Life Fear-Free”

2021 ◽  
Vol 8 (1) ◽  
pp. 54-68
Author(s):  
Lev Demidov ◽  
Igor Samoylenko ◽  
Nina Vand ◽  
Igor Utyashev ◽  
Irina Shubina ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Screening Program ◽  
Excisional Biopsy ◽  
Skin Lesions ◽  
Detection Methods ◽  
Non Melanoma Skin Cancer ◽  
The Social ◽  
Educational Campaign ◽  
Skin Cancer Detection ◽  
The Impact

Background: The screening program Life Fear-Free (LFF) aimed at early diagnosis of cutaneous melanoma (CM) was introduced in Samara, Chelyabinsk, Yekaterinburg, and Krasnodar (Russia) in 2019. Objectives: To analyze the impact of the program on early CM and non-melanoma skin cancer (NMSC) detection. Methods: According to the social educational campaign, people were informed about CM risk factors and symptoms and were invited for skin examination. The program planned to involve 3200 participants in total. Participants with suspicious lesions were invited for excisional biopsy. Results: 3143 participants, including 75.4% women, were examined for skin lesions. The average age of the participants was 43.7 years. Mostly skin phototypes II and III were registered (48.2% and 41.0%, respectively); 3 patients had CM, 15 had basal cell carcinoma, and 1 had Bowen’s disease, which were confirmed histologically. All detected melanomas had Breslow’s thickness of 1 mm. Conclusion: The participants showed high interest in early skin cancer detection programs. The incidence rate of CM and NMSCs among the program participants was higher than in general public. The early disease grade was proven for the detected CMs and NMSCs. The study has shown that it is important to continue such programs.

scholarly journals Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3359
Author(s):  
Elias Koch ◽  
Anne Petzold ◽  
Anja Wessely ◽  
Edgar Dippel ◽  
Anja Gesierich ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Uveal Melanoma ◽  
Hepatic Metastasis ◽  
Immune Checkpoint ◽  
Objective Response ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Response To Treatment ◽  
Extrahepatic Metastasis ◽  
The Impact

Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.

Sign in / Sign up

Export Citation Format

Share Document